Dapagliflozin Inhibits BK Polyomavirus Replication via AMPK Signaling
Journal of Medical Virology · 2026-11 · 98 (11)
DOI: 10.1002/jmv.71203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 29.10.2026. Verfasst von Yi-Jung Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, BK Virus, Virus Replication. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Science Council of Taiwan, Chung Gang Medical Research Project.
Abstract (Originalsprache)
BK polyomavirus (BKPyV) infection is a significant contributor of graft loss in kidney transplant recipients, yet no effective antiviral therapy is currently approved. This study investigated whether the SGLT2 inhibitor dapagliflozin could suppress BKPyV replication. BKPyV‐infected HK‐2 cells were treated with dapagliflozin, and viral load, protein expression, and noncoding control region (NCCR) transcriptional activity were analyzed. siRNA‐mediated knockdown of AMPK was used to verify its role in dapagliflozin‐mediated response. Dapagliflozin treatment at 10 and 20 μM resulted in a dose‐dependent suppression of BKPyV progeny release into the supernatant and a concomitant reduction in large T‐antigen (TAg) and VP1 protein expressions. These antiviral effects were achieved without compromising host cell viability, as no significant cytotoxicity was observed at the doses utilized. Luciferase reporter assays revealed that dapagliflozin markedly attenuated TAg‐driven NCCR transcriptional activity in both early and late orientations, effectively disrupting viral autoregulation. While high‐glucose conditions (25 mM) enhanced BKPyV replication and reduced baseline AMPK phosphorylation, the inhibitory efficacy of dapagliflozin remained consistent. Mechanistically, dapagliflozin increased AMPK phosphorylation even under hyperglycemic stress. The suppression of viral progeny and NCCR activity was significantly reversed upon AMPK knockdown, demonstrating that AMPK activation is required for dapagliflozin‐mediated viral suppression regardless of the glucose environment. Dapagliflozin inhibits BKPyV replication through an AMPK‐dependent pathway. These results provide a strong rationale for evaluating SGLT2 inhibitors as a novel strategy to reduce the severity of BKPyV infection in transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Department of Medicine, Chang Gung University, Taoyuan, Taiwan.
ORCID-Profile: Yu-Hsuan Chen, Jiun-Wen Wang, Hsiang-Hao Hsu, Ya-Chung Tian
Förderung
- National Science Council of Taiwan
- Chung Gang Medical Research Project
Zitieren
APA
Li, Y. J., Chen, Y. H., Wang, J. W., Wu, H. H., Hsu, H. H., Yang, C. W., & Tian, Y. C. (2026). Dapagliflozin Inhibits BK Polyomavirus Replication via AMPK Signaling. Journal of Medical Virology, 98(11). https://doi.org/10.1002/jmv.71203
Vancouver
Li YJ, Chen YH, Wang JW, Wu HH, Hsu HH, Yang CW, et al. Dapagliflozin Inhibits BK Polyomavirus Replication via AMPK Signaling. Journal of Medical Virology. 2026;98(11). doi:10.1002/jmv.71203
BibTeX
@article{Li2026,
author = {Li, Yi-Jung and Chen, Yu-Hsuan and Wang, Jiun-Wen and Wu, Hsin-Hsu and Hsu, Hsiang-Hao and Yang, Chih-Wei and Tian, Ya-Chung},
title = {Dapagliflozin Inhibits BK Polyomavirus Replication via AMPK Signaling},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {11},
doi = {10.1002/jmv.71203}
}
EUVIMED